Development
BioXcel Therapeutics, Inc.
BTAI
$1.84
$0.3120.26%
NASDAQ
| 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | 09/30/2022 | |
|---|---|---|---|---|---|
| Net Income | 5.66% | -1.36% | 3.67% | -31.10% | -10.98% |
| Total Depreciation and Amortization | -2.47% | 1.25% | -1.23% | -4.71% | 1.19% |
| Total Amortization of Deferred Charges | 5.90% | 6.91% | 3.42% | 48.39% | -32.40% |
| Total Other Non-Cash Items | -25.70% | 8.59% | 20.74% | -5.60% | 7.54% |
| Change in Net Operating Assets | -9.87% | 258.98% | -149.75% | 105.42% | 1,502.33% |
| Cash from Operations | 1.63% | 27.02% | -35.49% | -23.90% | 5.79% |
| Capital Expenditure | 100.00% | -- | -- | -- | 100.00% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | 100.00% | -- | -- | -- | 100.00% |
| Total Debt Issued | -- | -- | -- | -100.00% | -56.27% |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -100.00% | -99.00% | 49,730.00% | 4.17% | -74.05% |
| Repurchase of Common Stock | -- | 100.00% | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | 100.00% | -- | -- | 100.00% |
| Cash from Financing | -100.00% | -98.96% | 48,198.00% | -99.83% | -54.57% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 1.03% | -34.65% | 26.91% | -3,290.95% | -103.45% |